Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC10A2 | Q12908 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9961463 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL349300 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| SCHEMBL1993533 | 1.00 | SLC10A2 (1.00) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL8378730 | 0.99 | SLC10A2 (0.98) | SLC10A2 | |
| SCHEMBL13334949 | 0.93 | SLC10A2 (0.86) | SLC10A2 | |
| SCHEMBL8379990 | 0.93 | SLC10A2 (0.86) | SLC10A2 | |
| SCHEMBL8381989 | 0.92 | SLC10A2 (0.85) | SLC10A2 | |
| SCHEMBL8200833 | 0.92 | SLC10A2 (0.85) | SLC10A2 | |
| Hydrochloric Acid SCHEMBL8380609 | 0.92 | SLC10A2 (0.84) | SLC10A2 | |
| SCHEMBL8204051 | 0.91 | SLC10A2 (0.83) | SLC10A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0626952-B1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | WELLCOME FOUND (GB) | 1999-04-14 | — | — | EP | claimed |
| US-5663165-A | ANTICHOLESTEROL, CARDIOVASCULAR | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | claimed |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-01-19 | — | — | US | disclosed |
| EP-1535913-B1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | ASAHI KASEI PHARMA CORP (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-7973030-B2 | Benzothiazepine and benzothiepine compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-07-05 | — | — | US | disclosed |
| US-7803792-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-09-28 | — | — | US | disclosed |
| US-7312208-B2 | Quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-12-25 | — | — | US | disclosed |
| US-20070203115-A1 | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | ASHAI KASEI PHARAMA CORPORATION (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719768-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2006-11-08 | — | — | EP | disclosed |
| CN-1678597-A | Novel quaternary ammonium compounds | ASAHI KASEI PHARMA CORP (JP) | 2005-10-05 | — | — | CN | disclosed |
| EP-1535913-A1 | NOVEL QUATERNARY AMMONIUM COMPOUNDS | Asahi Kasei Pharma Corporation (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-0971744-A2 | COMBINATION THERAPY EMPLOYING ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 2000-01-19 | — | — | EP | disclosed |
| EP-0626952-B1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | WELLCOME FOUND (GB) | 1999-04-14 | — | — | EP | disclosed |
| US-5859240-A | REDUCTION OF IMINE GROUP; OXIDATION; SALT FORMATION | GLAXO WELLCOME INC. (US) | 1999-01-12 | — | — | US | disclosed |
| WO-1998040375-A2 | COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS | G.D. SEARLE & CO. (US) | 1998-09-17 | — | — | WO | disclosed |
| EP-0683773-B1 | HYPOLIPIDAEMIC CONDENSED 1,4-THIAZEPINES | WELLCOME FOUND (GB) | 1997-09-17 | — | — | EP | disclosed |
| US-5663165-A | ANTICHOLESTEROL, CARDIOVASCULAR | GLAXO WELLCOME INC. (US) | 1997-09-02 | — | — | US | disclosed |
| EP-0626952-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-12-07 | — | — | EP | disclosed |
| WO-1993016055-A1 | HYPOLIPIDAEMIC BENZOTHIAZEPINE COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203115-A1 | Novel quaternary ammonium compounds | SLC10A2, SLC10A1, ABCB11 | SLC10A2 1/4885 |
| US-20120015925-A1 | NOVEL BENZOTHIAZEPINE AND BENZOTHIEPINE COMPOUNDS | SLC10A1, SREBF1, SPTLC1 | SLC10A2 43/4885 |
| US-20070190041-A1 | Novel benzothiazepine and bensothiepine compounds | SLC10A1, GOT1, CES1 | SLC10A2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.